Chemical Property of Kirenol
Chemical Property:
- Melting Point:197.0 to 201.0 °C
- Refractive Index:1.57
- Boiling Point:516.902 °C at 760 mmHg
- PKA:14.06±0.20(Predicted)
- Flash Point:233.593 °C
- PSA：80.92000
- Density:1.177 g/cm3
- LogP:2.25190
- Storage Temp.:-20°C Freezer
- Solubility.:Ethanol (Slightly), Methanol (Slightly)
- XLogP3:2
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:3
- Exact Mass:338.24570956
- Heavy Atom Count:24
- Complexity:518
- Purity/Quality:
-
99%, *data from raw suppliers
Kirenol *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Safety Statements:
24/25
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1(CCC2C(=C1)CCC3C2(CC(CC3(C)CO)O)C)C(CO)O
- Isomeric SMILES:C[C@@]1(CC[C@@H]2C(=C1)CC[C@H]3[C@]2(C[C@@H](C[C@@]3(C)CO)O)C)[C@H](CO)O
-
Description
Kirenol is a diterpenoid that has been found in S. orientalis and has diverse biological activities, including anti-arthritic and anti-inflammatory properties. It inhibits Gram-positive and Gram-negative bacterial growth in disc diffusion assays with MICs ranging from 39 to 156 and 312.5 to 625 μg/ml, respectively. Kirenol also reduces K652 chronic myeloid leukemia cell viability with a 48 hour IC50 value of 18.19 μg/ml and induces apoptosis. In vivo, kirenol (2 mg/kg, p.o.) reduces motor deficit, delays disease onset by approximately five days, and downregulates inflammatory CD4+IFN-γ+ Th1 cells and CD4+IL-17A+ Th17 cells in a mouse model of experimental autoimmune encephalomyelitis (EAE). Intragastric administration of kirenol (1-4 mg/kg) reduces the arthritis index, NF-kB activity, and paw swelling and increases annexin-1 expression without affecting glucocorticoid receptor α (GRα) expression in the synovium in a rat model of collagen-induced arthritis. Topical administration of kirenol (0.3-0.5% w/w) reduces edema induced by carrageenan, complete Freund''s adjuvant (CFA), and formalin in rats up to 44, 67, and 65%, respectively.
-
Uses
Kirenol is a pharmaceutical agent that induces apoptosis in human chronic myeloid leukemia cells.
